Intraoperative imaging using a mobile computed tomography scanner.

H Gumprecht; C B Lumenta

doi:10.1055/s-2003-812496

Home/Archive/PubMed

PubMed · 14968395

Intraoperative imaging using a mobile computed tomography scanner.

H Gumprecht·C B Lumenta

View original source ↗Export metadata ↓

Abstract

OBJECTIVE: The radicality of tumour removal in patients suffering from glioma is discussed to be an important factor for longer survival times. Therefore intraoperative imaging modalities like magnetic resonance imaging (MRI), computed tomography (CT) and ultrasound (US) are tested in many neurosurgical facilities for clinical use. In our department a mobile CT for intraoperative applications is used for this purpose since 1999. The handling and useful application of the mobile CT scanner as well as results without intraoperative imaging are discussed. MATERIAL AND METHODS: 470 CT scans with the mobile CT were accomplished, including 270 cases of neuronavigation planning, 76 cases of intraoperative scans, 48 cases of postoperative scans, 69 CT scans for stereotactic biopsy planning and control as well as 3 cases of emergency scanning in trauma patients and 4 spine applications. The results of the intraoperative CT scans are compared with those of the postoperative MRI scans. Additionally 87 patients with glioma were evaluated. These patients underwent surgery without intraoperative imaging. RESULTS: In 27 out of 43 patients with glioma residual tumour was detected with intraoperative CT. In 13 cases the surgery was resumed to complete resection, in 14 cases the operation was not continued due to close vicinity to eloquent areas or difficulties in image interpretation. In 44 cases the results of intraoperative CT and postoperative MRI were compared. In 6 cases the MRI demonstrated residual tumour in contrast to the results of the CT scans. In 3 cases the tumour removal could have been more complete (6.8 %). In 87 cases glioma surgery was performed without intraoperative CT. In 6 cases a more complete tumour removal could have been performed (6.9 %) according to the results of postoperative MRI. CONCLUSION: Intraoperative imaging with a mobile CT scanner is a good method for detection of residual tumour. The CT scanner can be integrated in an operative setting without problems. Although intraoperative imaging can be helpful in some selected cases, most of the neurosurgical procedures can be well performed with proper neuronavigation planning.

Explore related subjects

Brain Neoplasms Glioma Humans Magnetic Resonance Imaging Monitoring, Intraoperative Neoplasm, Residual Neuronavigation Tomography Scanners, X-Ray Computed Tomography, X-Ray Computed Treatment Outcome Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

H Gumprecht, C B Lumenta. 2003. Intraoperative imaging using a mobile computed tomography scanner.. https://doi.org/10.1055/s-2003-812496

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Leveraging single-cell and spatial omics for brain tumour insights to improve therapeutic strategies.

Single-cell and spatial omics (SPOs) technologies have advanced how healthcare physicians characterise brain tumours by enabling detailed understanding of their cellular architecture, functional states, and microenvironmental dynamics. These approaches provide high-resolution detection of tumour heterogeneity and allow precise analysis of the brain tumour microenvironment. Their application has also led to the discovery of novel biomarkers used for early brain tumour detection, prognosis, and improved tumour stratification. Furthermore, integrative multi-omic analyses have revealed new therapeutic targets, clarified mechanisms of drug resistance, and uncovered molecular pathways underpinning treatment failure. By bridging cellular-level insights with spatial context, SPOs hold significant promise for advancing personalised diagnostics, predicting therapeutic response, and guiding the development of targeted interventions for brain tumours. Despite these advances, several limitations constrain the full translational potential of SPOs, including high experimental costs, substantial computational demands, lack of standardised protocols, and challenges in data integration and reproducibility. Addressing these barriers through scalable bioinformatic pipelines, consensus experimental frameworks, and cost-effective platforms remains critical for broadening accessibility and enabling clinical adoption.

Brain Neoplasms↗

PubMed2026

Identification of Critical Genes Related to Breast Cancer with Brain Metastasis Through Bioinformatics Analysis.

INTRODUCTION: Distant metastasis accounts for the majority of Breast Cancer (BC)-related mortality. The brain is one of the most common regions of metastasis. However, the underlying molecular mechanisms remain uncertain. METHODS: In this study, gene expression profiles were downloaded from the Gene Expression Omnibus (GEO) database. Datasets GSE100534 and GSE52604, containing 16 primary brain tumor samples and 38 breast cancer brain metastasis samples, were used to identify the Differentially Expressed Genes (DEGs). The Metascape database was used to analyze enriched Gene Ontology (GO) entries and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway entries in DEGs. The STRING database was then used to construct a Protein-Protein Interaction (PPI) network, and the Cytoscape platform was employed to visualize the network. Furthermore, the Kaplan-Meier curve was used to analyze the Relapse-Free Survival (RFS) among the hub genes. Finally, the iRegulon plugin was used to construct a regulatory network to find the transcription factors (TFs) that regulate the expression of the hub genes. RESULTS: A total of 344 DEGs, including 182 up-regulated and 162 down-regulated genes, were identified by using the limma package in R. A module with 18 nodes and 9 hub genes was selected from the PPI network by using the plugins MCODE and Cyto- Hubba, respectively. KEGG pathway analysis demonstrated that brain metastasis in BC was closely related to the oocyte cell cycle. The Kaplan-Meier curve showed that high expression of these 9 hub genes was associated with poor RFS in BC patients. TFs' analysis showed that E2F4, SIN3A, FOXM1, and TFDP1 interacted with these hub genes. DISCUSSION: This study revealed that Breast Cancer Brain Metastasis (BCBM) may have a promoting effect on the cell cycle of oocytes and affect the maturation and division of oocytes through the KEGG and GO analyses of 344 DEGs. The selected 9 hub genes (ASPM, BUB1, BUB1B, CCNA2, CCNB1, CDK1, NDC80, NCAPG, and TOP2A) and 4 transcription factors (E2F4, SIN3A, FOXM1, TFDP1) may play a critical role in brain metastasis of BC. CONCLUSION: The results of this study may aid in the early diagnosis and suggest potential targets for the treatment of BCBM.

Brain Neoplasms↗

PubMed2024

Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites.

Brain metastasis of advanced breast cancer often results in deleterious consequences. Metastases to the brain lead to significant challenges in treatment options, as the blood-brain barrier (BBB) prevents conventional therapy. Thus, we hypothesized that creation of a nanoparticle (NP) that distributes to both primary tumor site and across the BBB for secondary brain tumor can be extremely beneficial. Here, we report a simple targeting strategy to attack both the primary breast and secondary brain tumors utilizing a single NP platform. The nature of these mitochondrion-targeted, BBB-penetrating NPs allow for simultaneous targeting and drug delivery to the hyperpolarized mitochondrial membrane of the extracranial primary tumor site in addition to tumors at the brain. By utilizing a combination of such dual anatomical distributing NPs loaded with therapeutics, we demonstrate a proof-of-concept idea to combat the increased metabolic plasticity of brain metastases by lowering two major energy sources, oxidative phosphorylation (OXPHOS) and glycolysis. By utilizing complementary studies and genomic analyses, we demonstrate the utility of a chemotherapeutic prodrug to decrease OXPHOS and glycolysis by pairing with a NP loaded with pyruvate dehydrogenase kinase 1 inhibitor. Decreasing glycolysis aims to combat the metabolic flexibility of both primary and secondary tumors for therapeutic outcome. We also address the in vivo safety parameters by addressing peripheral neuropathy and neurobehavior outcomes. Our results also demonstrate that this combination therapeutic approach utilizes mitochondrial genome targeting strategy to overcome DNA repair-based chemoresistance mechanisms.

Brain Neoplasms↗